NCT04683939
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
Phase: Phase 1/2
Role: Lead Sponsor
Start: Jan 18, 2022
Completion: Jul 24, 2023